Asish Xavier

Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA.

Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia.

iScience Interventional Corp. discovers and develops microcatheter and imaging technologies that enable ophthalmologists to deliver site-specific ocular therapies. It encompasses microcatheter-based therapies designed to access anatomical structures within the eye to aspirate ocular fluids or deliver sterile ophthalmic solutions to the eye. The firm addresses the previously unmet need for treatment of sight-threatening diseases with the innovative, minimally invasive iCath™ procedures. The company was founded by Michael F. Nash and Stan Conston in 1999 and is headquartered in Menlo Park, CA.

Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA.

Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA.

Message Pharmaceuticals, Inc. develops pharmaceutical drugs. It operates as research development company involved in RNA research and exploring other types of RNAs to look for RNA-binding proteins, especially to combat RNA viruses and to treat all major disease categories. Message Pharmaceuticals was founded in 2002 and is located in Malvern, PA

Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA.

Verana Health, Inc. engages in the development of software solutions for remote patient monitoring and data analytics. It focuses on bridging the gap between healthcare providers and patients with mobile tests. The company was founded by Mark S. Blumenkranz and Daniel V. Palanker in 2008 and is headquartered in San Francisco, CA.

Lodo Therapeutics Corp. engages in the development of novel therapeutics from its metagenomics-based small molecule discovery platform. Its Lodo platform leverages breakthroughs in next-generation sequencing (NGS), artificial intelligence (AI), and machine learning (ML), along with advances in synthetic biology and automation. The company was founded by Sean Brady and David L. Pompliano and is headquartered in New York, NY.

Petra Pharma Corp. operates as a drug development company that develops novel small molecules for the treatment of cancer and metabolic diseases. The company was founded by Lewis Clayton Cantley and Nathanael S. Gray in 2016 and is headquartered in New York, NY.

Xwpharma operates as a biopharmaceutical company. It focuses on eveloping a portfolio of internally discovered product candidates for the treatment of neurological disorders. The company was founded by Jia-Ning Xiang and is headquartered in Wuhan, China.

ESCAPE Bio, Inc. is a preclinical stage biopharmaceutical company. It focuses on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. The company was founded by Robert Mahley and Yadong Huang in 2015 and is headquartered in San Francisco, CA.

Rodeo Therapeutics Corp. engages in the development of drugs. The firm develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It focuses on the development of small-molecule therapies that increase tissue levels of prostaglandin PGE2. The company was founded by Stanton Gerson, Sanford Markowitz, and Joseph Ready on May 15, 2017 and is headquartered in Seattle, WA.

Proniras Corp. operates as a bio technology company. The company is headquartered in Seattle, WA.

Paige Ai, Inc. engages in revolutionizing pathology and strengthen lynchpin of medical diagnostics with quantitative, computational technology, fusing machine learning, and human expertise. It involves in building an artificial intelligence to change clinical diagnosis and treatment of cancer. The company is headquartered in New York, NY.

Aquinox Pharmaceuticals (Canada), Inc. manufactures pharmaceuticals for blood caner treatment. The company is headquartered in Vancouver, Canada.

ImmPACT Bio USA, Inc. operates as a cell therapy company. The firm develops potent and selective engineered T-cells for the treatment of solid tumors. The company is headquartered in Camarillo, CA.

Part of Accelerator Services Corp, Accelerator Life Science Partners II LP functions as a venture capital fund. The private company is based in Seattle, WA.

SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation.